MiMedX Group (Seite 4)

[Charly_2]

Antwort auf Beitrag Nr.: 64.087.536 von Charly_2 am 19.06.20 13:40:40

MiMedx zurück an der Nasdaq :-)

Aktie bei $5,94

Projektion by James on Yahoo Board

Below are my sales and fair value estimates that I posted a few months back for the next 36 and 48 months. The sales forecast is a run rate… which means the monthly sales for 12/31/20 will be 29.16 per month…. After the third quarter, my forecast has not changed… As of today, my MDXG fair value is in a band of $10 to 12 per share… To maximize our returns and minimize the risk in this position, I would advise extending your horizon to a minimum of 12 to 18 months…. Although the stock has 250 million is sales roughly……. It is going to take some time to rebuild the US sales team, expand marketing internationally, and to get FDA approval for the injectables…. Although my forecast seems aggressive… they may prove conservative once new products get the FDA go ahead….. Just forget this stock for a while… this is a 7 to 10 bagger….
James the Accountant…
12/31/20 350m, $15, by 2/21
12/31/21 500m, $25 by 2/22
12/31/23 1000, $50 by 2/24

[Charly_2]

Aktie bei $5.50, OTC Segment

Q-Report wird erwartet, danach Relisting an NASDAQ

[Charly_2]

Aktie bei $5.28

https://www.bloomberg.com/opinion/articles/2019-08-22/mimedx…

Auszug:

MiMedx Has Changed, But Its Critics Haven’t

Doctors who use its products say it’s because they work. New investors have high expectations. So why haven’t the shorts let go?

By Joe Nocera

22. August 2019, 18:35 MESZ

Maybe EpiFix can help.

Source: BSIP/Universal Images Group Editorial/Getty Images

Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."

Read more opinionFollow @opinion_joe on Twitter

This is the second of two columns about MiMedx and the short-sellers. Read the first here.

Most of the time, Eiad Asbahi, the 40-year-old founder of Prescience Point Capital Management, is a short-seller.

According to its website, the firm, based in Baton Rouge, Louisiana, specializes “in extensive investigations of difficult-to-analyze public companies in order to uncover significant elements of the business that have been overlooked or ignored by others.” Such investigations usually lead to the discovery of problems that will cause the stock to fall once they become known.

“But every now and then,” Asbahi says, “we find a company that is incredibly hated and where the shorts have it wrong.” SeaWorld Entertainment Inc., which has been hammered for its treatment of its whales and dolphins, was one such company. Two years ago, Asbahi bought the stock, believing that “the mispricing was extreme.” He was right. Since it bottomed out in November 2017, SeaWorld’s shares have more than tripled.

On Jan. 8 of this year, Prescience Point released a report about its latest big investment idea: MiMedx Group Inc., a company that was under siege by Marc Cohodes and a handful of other short-sellers. After six months of research, Asbahi concluded that the thesis developed by the shorts — which had helped push the stock from $18 to $1.15 — was wrong.

Contrary to what Cohodes et al were claiming, Prescience Point’s research suggested that MiMedx products were “legitimate and sustainable”; that it had positive cash flow; and that, while “channel stuffing” to improperly boost revenue at the end of the quarter had taken place, the company’s critics had “failed to produce any smoking guns to support their claims of massive fraud.”

“In our view MDXG is one of the largest mispricings we have ever identified,” the report concluded. At the time it was issued, MiMedx stock was at $2.16. Prescience Point predicted that it would quadruple

[Charly_2]

Preis aktuell: $5.25 - OTC-Börse

[Pebbles]

MiMedx® delivers innovative bioactive healing products for tissue regeneration

MiMedx® is the global premier processor, marketer, and distributor of human amniotic tissue. MiMedx® has distributed over 1,000,000 amniotic tissue grafts worldwide and achieved profound clinical outcomes in multiple therapeutic areas including ophthalmology, spine, chronic wounds, dental, orthopedic surgery, sports medicine, and urology. With this groundbreaking human tissue offering that promotes bioactive healing, MiMedx® believes its unmatched knowledge and superior processing of amniotic tissue strategically positions the Company to become the leader in regenerative medicine. (aus: https://www.mimedx.com/)

Aktuelles Quartalsergebnis

MiMedx Group, Inc (NASDAQ:MDXG) issued its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07, Bloomberg Earnings reports. The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $74.22 million. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The business’s quarterly revenue was up 33.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 earnings per share. MiMedx Group updated its FY17 guidance to $0.31-0.33 EPS.

Shares of MiMedx Group (MDXG) traded up 7.516% during trading on Tuesday, hitting $16.966. 2,877,111 shares of the stock were exchanged. MiMedx Group has a one year low of $6.94 and a one year high of $17.11. The stock has a market cap of $1.82 billion, a PE ratio of 89.295 and a beta of 1.03. The stock’s 50 day moving average price is $14.97 and its 200 day moving average price is $12.10.

aus: https://www.thecerbatgem.com/2017/08/15/mimedx-group-inc-nas…

Chart 6 Monate